UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): January 26, 2011
Clenergen
Corporation
(Exact
name of registrant as specified in its charter)
Nevada | 333-130286 | 20-2781289 |
(State or
other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
Bath
House
8
Chapel Place
London
EC2A EDQ
United
Kingdom
|
Not applicable | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code: +44 (0)
20773900289
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Introductory
Comment - Use of Terminology
Throughout
this Current Report on Form 8-K, the terms” “we,” “us” and “our” refers to the
registrant, Clenergen Corporation, and, where applicable, its wholly-owned
subsidiaries, including Clenergen India Private Limited (“Clenergen India”), on
a consolidated basis.
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Robert
Kohn submitted his resignation as a director of our company on January 26,
2011. Mr. Kohn noted in his resignation letter that he was submitting
his resignation since he believed there was a conflict of interest between his
position as one of our directors and his position with BioPower Corporation, a
licensee of certain of our intellectual property for use in the United States,
Central America, Mexico, Guam and Cuba.
We have
provided Robert Kohn with a copy of disclosures contained in this Current Report
on Form 8-K prior to the filing of this Form 8-K and given him an opportunity to
furnish us as promptly as possible with a letter stating whether or not he
agrees with such disclosures and, if not, stating the respects in which he does
not agree. We have not, to the time of filing this Form 8-K,
received any such letter from Mr. Kohn.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: January 31, 2011 | Clenergen Corporation | ||
|
By:
|
/s/ Tim Bowen | |
Tim Bowen | |||
Chief Executive Officer | |||